UPDATE: Moderna (MRNA) PT Raised to 'Street High' $105 at Goldman Sachs
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Price: $60.42 --0%
Rating Summary:
5 Buy, 21 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 1 | New: 4
Rating Summary:
5 Buy, 21 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 1 | New: 4
Join SI Premium – FREE
(Updated - May 18, 2020 10:00 AM EDT)
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and raised his price target on Moderna (NASDAQ: MRNA) to $105.00 (from $63.00) following positive COVID vaccine data.
The price target is a new 'Street High'.
For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.
Shares of Moderna closed at $66.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
- Rheinmetall AG (RHM:GR) (RNMBY) PT Lowered to EUR1,750 at Morgan Stanley
- Ajinomoto (2802:JP) (AJINY) PT Raised to JPY7,100 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot Comments, Momentum Movers, Trader TalkRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
